Full-service CRO + RWD/RWE data moat. Multi-year contracts and backlog insulate. Largest health-data catalog creates a durable competitive advantage. Paid to run trials regardless of outcome.
Conviction●○○○○1 of 5
Research target—Snapshot target
Thesis statusNEEDS_MORE_DATALast reviewed Not reviewed
Market cap34.55BSnapshot value
R&D funding at decade highs (~$102B in 2024); RWE regulatory acceptance for approvals/labels; AI-clinical analytics partnership (Veeva) expanding service scope; BIOSECURE reshoring tailwind.
Biotech funding volatility (hits small-client-levered CROs first); elevated cancellations/rebids; part of multiple rides AI-analytics narrative — not purely decoupled; China exposure.
needs X/Reddit sentiment sweep
Snapshot · Not reviewed🟢 Lean-Bull · 13F 18+/7- · short↑0.26
Snapshot · Not reviewed